JP2020508329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508329A5 JP2020508329A5 JP2019546144A JP2019546144A JP2020508329A5 JP 2020508329 A5 JP2020508329 A5 JP 2020508329A5 JP 2019546144 A JP2019546144 A JP 2019546144A JP 2019546144 A JP2019546144 A JP 2019546144A JP 2020508329 A5 JP2020508329 A5 JP 2020508329A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric protein
- tim3
- cd40l
- domain
- ox40l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130749A JP2022159510A (ja) | 2017-02-27 | 2022-08-18 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464002P | 2017-02-27 | 2017-02-27 | |
| US62/464,002 | 2017-02-27 | ||
| PCT/US2018/020040 WO2018157165A1 (en) | 2017-02-27 | 2018-02-27 | Methods of making and using extracellular domain-based chimeric proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130749A Division JP2022159510A (ja) | 2017-02-27 | 2022-08-18 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508329A JP2020508329A (ja) | 2020-03-19 |
| JP2020508329A5 true JP2020508329A5 (enExample) | 2021-04-08 |
| JP7128195B2 JP7128195B2 (ja) | 2022-08-30 |
Family
ID=63253416
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546144A Active JP7128195B2 (ja) | 2017-02-27 | 2018-02-27 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
| JP2019546149A Active JP7260477B2 (ja) | 2017-02-27 | 2018-02-27 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
| JP2022130749A Pending JP2022159510A (ja) | 2017-02-27 | 2022-08-18 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
| JP2023062366A Active JP7620045B2 (ja) | 2017-02-27 | 2023-04-06 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
| JP2025003769A Withdrawn JP2025061180A (ja) | 2017-02-27 | 2025-01-09 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546149A Active JP7260477B2 (ja) | 2017-02-27 | 2018-02-27 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
| JP2022130749A Pending JP2022159510A (ja) | 2017-02-27 | 2022-08-18 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
| JP2023062366A Active JP7620045B2 (ja) | 2017-02-27 | 2023-04-06 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
| JP2025003769A Withdrawn JP2025061180A (ja) | 2017-02-27 | 2025-01-09 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US11332509B2 (enExample) |
| EP (2) | EP3585425A4 (enExample) |
| JP (5) | JP7128195B2 (enExample) |
| KR (1) | KR102745835B1 (enExample) |
| CN (3) | CN118994414A (enExample) |
| AU (2) | AU2018223821B2 (enExample) |
| BR (1) | BR112019017298A2 (enExample) |
| CA (2) | CA3054127A1 (enExample) |
| IL (2) | IL268198B2 (enExample) |
| MX (1) | MX2019009812A (enExample) |
| MY (1) | MY207687A (enExample) |
| PH (1) | PH12019501533A1 (enExample) |
| SG (1) | SG11201906465YA (enExample) |
| WO (2) | WO2018157162A1 (enExample) |
| ZA (1) | ZA201905488B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118994414A (zh) | 2017-02-27 | 2024-11-22 | 沙塔克实验室有限公司 | 基于tigit和light的嵌合蛋白 |
| JP7511469B2 (ja) | 2017-09-27 | 2024-07-05 | イノザイム ファーマ， インコーポレイテッド | 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。 |
| CA3103975A1 (en) * | 2018-06-21 | 2019-12-26 | Shattuck Labs, Inc. | Heterodimeric proteins and uses thereof |
| AU2019327493A1 (en) * | 2018-08-29 | 2021-03-04 | Shattuck Labs, Inc. | Combination therapies comprising sirp alpha-based chimeric proteins |
| CA3109349A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Combination therapies comprising tim-3-based chimeric proteins |
| CN112912384A (zh) * | 2018-08-29 | 2021-06-04 | 沙塔克实验室有限公司 | 组合疗法 |
| CA3110498A1 (en) * | 2018-08-31 | 2020-03-05 | Yale University | Enpp1 polypeptides and methods of using same |
| SG11202102272UA (en) * | 2018-09-05 | 2021-04-29 | Univ Arizona State | Oncolytic virus platform to treat hematological cancer |
| EP3906038A4 (en) | 2018-11-21 | 2022-06-01 | Mayo Foundation for Medical Education and Research | ADENOVIRUS AND METHODS OF USE OF ADENOVIRUS |
| EP3930851A4 (en) * | 2019-02-28 | 2023-03-29 | Shattuck Labs, Inc. | COMBINATION THERAPIES |
| AU2020266125B2 (en) * | 2019-04-29 | 2023-04-13 | Mayo Foundation For Medical Education And Research | Multivalent PD-L1 binding compounds for treating cancer |
| CN112111437B (zh) * | 2020-05-25 | 2023-09-05 | 江南大学 | 2’-岩藻糖基乳糖产量提高的重组枯草芽孢杆菌及其构建方法 |
| US11820824B2 (en) * | 2020-06-02 | 2023-11-21 | Arcus Biosciences, Inc. | Antibodies to TIGIT |
| CN115916348A (zh) | 2020-06-18 | 2023-04-04 | 基因泰克公司 | 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗 |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| CN111808800B (zh) * | 2020-07-20 | 2022-08-26 | 中南大学湘雅二医院 | 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用 |
| IL301454A (en) * | 2020-09-17 | 2023-05-01 | Shattuck Labs Inc | Clinical dosing of SIRP1A chimeric protein |
| EP4237000A4 (en) * | 2020-11-02 | 2024-09-18 | Athae Bio, Inc. | TWO-DOMAIN MULTIMERIC FUSION PROTEINS |
| WO2022120191A1 (en) * | 2020-12-03 | 2022-06-09 | Shattuck Labs, Inc. | Methods of treating cancer using tigit-and light-based chimeric proteins |
| CN116897202A (zh) * | 2021-02-24 | 2023-10-17 | 科济生物医药（上海）有限公司 | Tigit工程化细胞及其组合物 |
| CN115260312B (zh) * | 2021-04-30 | 2025-02-14 | 保诺科技（北京）有限公司 | 结合ox40的抗体或抗原结合片段 |
| TW202320848A (zh) | 2021-07-28 | 2023-06-01 | 美商建南德克公司 | 治療癌症之方法及組成物 |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| CN115960247A (zh) * | 2021-10-13 | 2023-04-14 | 苏州科锐迈德生物医药科技有限公司 | 基于t7rna聚合酶的融合多肽及其制备方法、用途 |
| JP2024543025A (ja) * | 2021-11-01 | 2024-11-19 | シャタック ラボ，インコーポレイテッド | 皮膚炎症治療のためのキメラタンパク質 |
| CN114209815B (zh) * | 2021-11-22 | 2024-04-26 | 山东大学 | 一种药物组合物及其制备方法和应用 |
| WO2023105281A1 (en) * | 2021-12-11 | 2023-06-15 | Fundaciò Privada Institut De Recerca De La Sida-Caixa | Soluble tigit recombinant proteins |
| CN115490771B (zh) * | 2021-12-24 | 2026-04-28 | 合肥天港免疫药物有限公司 | 重组抗体及其应用 |
| CN114196691B (zh) * | 2021-12-28 | 2023-08-11 | 重庆澳龙生物制品有限公司 | 一种制备防治牛、羊棘球蚴病多表位重组疫苗的基因、蛋白质、疫苗和应用 |
| IL317449A (en) | 2022-06-07 | 2025-02-01 | Genentech Inc | Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist |
| CN117624375A (zh) * | 2022-08-30 | 2024-03-01 | 北京卡替医疗技术有限公司 | 增强受体、表达增强受体的免疫细胞及其用途 |
| CN116350748A (zh) * | 2022-11-01 | 2023-06-30 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | Tigit融合蛋白在制备用于治疗系统性红斑狼疮药物中的应用 |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| CN116041542B (zh) * | 2022-12-06 | 2026-02-17 | 上海恩凯细胞技术有限公司 | 逆转肿瘤微环境抑制性信号的nk细胞制备方法及应用 |
| CN116037072B (zh) * | 2023-02-24 | 2025-01-03 | 宁夏医科大学 | 一种血清抗体亲和分离材料的制备方法与应用 |
| CN116925236B (zh) * | 2023-05-12 | 2024-06-04 | 上海恩凯细胞技术有限公司 | 嵌合转换受体及其应用 |
| AU2024314312A1 (en) * | 2023-06-22 | 2025-10-30 | Fbd Biologics Limited | Multi-targeting protein complex and methods of use thereof |
| CN116982600B (zh) * | 2023-09-14 | 2025-11-18 | 江苏集萃药康生物科技股份有限公司 | 一种cd69人源化小鼠模型的构建方法及其应用 |
| CN119930791A (zh) * | 2023-11-02 | 2025-05-06 | 重庆精准生物技术有限公司 | 特异性tigit肽段 |
| WO2025140345A1 (zh) * | 2023-12-29 | 2025-07-03 | 沈阳三生制药有限责任公司 | 一种tigit多肽及tigit/ctla4融合蛋白 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| KR100283541B1 (ko) | 1991-10-25 | 2001-03-02 | 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 | 신규 사이토킨 |
| ATE360031T1 (de) | 2000-01-03 | 2007-05-15 | Tr Associates L L C | Chimäre proteine und anwendungen |
| US20110041190A1 (en) | 2002-10-31 | 2011-02-17 | Tykocinski Mark L | Novel chimeric proteins |
| US7696168B2 (en) * | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| EP1685159B1 (en) | 2003-10-03 | 2012-08-01 | Brigham & Women's Hospital | Tim-3 polypeptides |
| WO2005047337A1 (en) | 2003-11-13 | 2005-05-26 | Hanmi Pharmaceutical Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
| JP2006345852A (ja) | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| US20080131431A1 (en) | 2006-05-15 | 2008-06-05 | Viral Logic Systems Technology Corp. | CD47 related compositions and methods for treating immunological diseases and disorders |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| EP2038303A2 (en) | 2006-06-21 | 2009-03-25 | Genentech, Inc. | Crystal structure of ox40l and ox40l complexed with ox40 receptor |
| US20100150931A1 (en) | 2006-11-22 | 2010-06-17 | Centre Hospitalier De L'universite De Montreal | Novel receptor for cd40l and uses thereof |
| WO2008144029A1 (en) | 2007-05-14 | 2008-11-27 | The University Of Chicago | Antibody-light fusion products for cancer therapeutics |
| PT2242512T (pt) | 2008-01-15 | 2016-07-18 | Univ Leland Stanford Junior | Métodos para manipular a fagocitose mediada por cd47 |
| WO2009114110A1 (en) | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| EP2460827A1 (en) | 2008-06-30 | 2012-06-06 | The Trustees Of The University Of Pennsylvania | Fusion proteins comprising Fn14 and an inhibitory protein |
| KR20110044992A (ko) | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＧＦ-β 길항제 다중-표적 결합 단백질 |
| EP3103875A1 (en) | 2008-07-21 | 2016-12-14 | Apogenix AG | Tnfsf single chain molecules |
| US8183207B2 (en) | 2008-11-26 | 2012-05-22 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules |
| US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
| CN102257001A (zh) * | 2008-12-19 | 2011-11-23 | 诺瓦提斯公司 | 治疗自体免疫和炎性病症的可溶性多肽 |
| US9221895B2 (en) | 2009-03-13 | 2015-12-29 | The Trustees Of The University Of Pennsylvania | OX40/TRAIL fusion proteins |
| PT2542590T (pt) | 2010-03-05 | 2017-08-31 | Univ Johns Hopkins | Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados |
| CN103153332A (zh) | 2010-09-28 | 2013-06-12 | 卡尔医疗有限公司 | 用于治疗血液恶性肿瘤的组合物和方法 |
| CN103261217B (zh) | 2010-11-11 | 2017-04-26 | 港大科桥有限公司 | 可溶性 pd‑1变体、融合构建体及其用途 |
| ES2608835T3 (es) | 2011-04-13 | 2017-04-17 | Bristol-Myers Squibb Company | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones |
| US10179164B2 (en) | 2011-05-25 | 2019-01-15 | Cel-Sci Corporation | Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions |
| CN102850458B (zh) * | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| PH12014500247A1 (en) | 2011-07-29 | 2014-03-24 | Univ Pennsylvania | Switch costimulatory receptors |
| US9828432B2 (en) | 2012-02-06 | 2017-11-28 | Providence Health & Services—Oregon | Cancer treatment and monitoring methods using OX40 agonists |
| WO2013164694A1 (en) | 2012-04-30 | 2013-11-07 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
| ES2924722T3 (es) | 2012-05-18 | 2022-10-10 | Aptevo Res & Development Llc | Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3 |
| CN103566377A (zh) | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| HRP20192013T1 (hr) | 2012-12-17 | 2020-02-07 | Trillium Therapeutics Inc. | Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama |
| AU2013371826A1 (en) * | 2013-01-01 | 2015-08-13 | Kahr Medical Ltd. | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
| US20140242077A1 (en) | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| US10533054B2 (en) | 2013-01-31 | 2020-01-14 | Thomas Jefferson University | Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system |
| EP2951199A4 (en) | 2013-01-31 | 2016-07-20 | Univ Jefferson | Fusion proteins for the modulation of regulatory and effector T cells |
| WO2014121093A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| WO2015116178A1 (en) | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
| US9657082B2 (en) | 2013-01-31 | 2017-05-23 | Thomas Jefferson University | PD-L1 and PD-L2-based fusion proteins and uses thereof |
| BR112015020516A2 (pt) | 2013-02-26 | 2017-10-10 | Memorial Sloan Kettering Cancer Center | composições e métodos para imunoterapia |
| PL2970512T3 (pl) | 2013-03-12 | 2019-03-29 | Biocon Limited | Immunomodulujące białka fuzyjne i sposoby ich otrzymywania |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| US10144770B2 (en) * | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| US10196435B2 (en) | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
| WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| US10927154B2 (en) | 2014-01-13 | 2021-02-23 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| WO2015107331A2 (en) | 2014-01-14 | 2015-07-23 | Kymab Limited | Anti-light antibodies |
| CA2936244A1 (en) | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| CN106459218B (zh) | 2014-03-24 | 2021-03-02 | 宜明昂科生物医药技术（上海）有限公司 | 新的重组双功能融合蛋白、其制剂和用途 |
| EP3148573A4 (en) | 2014-05-29 | 2017-11-15 | Medimmune, LLC | Ox40l fusion proteins and uses thereof |
| EP3160497A4 (en) | 2014-06-27 | 2018-01-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Conjugates for immunotherapy |
| WO2016023040A1 (en) | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| SI3482766T1 (sl) | 2014-08-11 | 2020-09-30 | Delinia, Inc. | Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni |
| DK3180363T3 (da) | 2014-08-15 | 2019-11-04 | Merck Patent Gmbh | Sirp-alpha-immunoglobulin fusionsproteiner |
| EP3221360A1 (en) | 2014-11-17 | 2017-09-27 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| JP2018505911A (ja) | 2014-12-05 | 2018-03-01 | イミュネクスト，インコーポレーテッド | 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用 |
| WO2016112983A1 (en) * | 2015-01-15 | 2016-07-21 | Biontech Ag | Cytokine fusion proteins |
| US11161907B2 (en) * | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| KR20170109582A (ko) | 2015-02-06 | 2017-09-29 | 히트 바이오로직스, 인코퍼레이티드 | 벡터 공동 발현 백신 및 공동 자극 분자 |
| WO2016166139A1 (en) | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
| US9845345B2 (en) | 2015-05-18 | 2017-12-19 | Ab Initio Biotherapeutics, Inc. | SIRP polypeptide compositions and methods of use |
| WO2017027422A1 (en) | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
| BR112018006578A2 (pt) | 2015-10-01 | 2018-12-26 | Heat Biologics, Inc. | composições e métodos para juntar domínios extracelulares tipo i e tipo ii como proteínas quiméricas heterólogas |
| WO2018075960A1 (en) | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| CN118994414A (zh) * | 2017-02-27 | 2024-11-22 | 沙塔克实验室有限公司 | 基于tigit和light的嵌合蛋白 |
-
2018
- 2018-02-27 CN CN202410811167.XA patent/CN118994414A/zh active Pending
- 2018-02-27 IL IL268198A patent/IL268198B2/en unknown
- 2018-02-27 MX MX2019009812A patent/MX2019009812A/es unknown
- 2018-02-27 CN CN201880009524.3A patent/CN110234345A/zh active Pending
- 2018-02-27 MY MYPI2019004825A patent/MY207687A/en unknown
- 2018-02-27 IL IL313003A patent/IL313003A/en unknown
- 2018-02-27 EP EP18757341.5A patent/EP3585425A4/en not_active Withdrawn
- 2018-02-27 JP JP2019546144A patent/JP7128195B2/ja active Active
- 2018-02-27 SG SG11201906465YA patent/SG11201906465YA/en unknown
- 2018-02-27 JP JP2019546149A patent/JP7260477B2/ja active Active
- 2018-02-27 KR KR1020197023430A patent/KR102745835B1/ko active Active
- 2018-02-27 US US16/484,852 patent/US11332509B2/en active Active
- 2018-02-27 AU AU2018223821A patent/AU2018223821B2/en active Active
- 2018-02-27 US US16/484,850 patent/US20190367579A1/en not_active Abandoned
- 2018-02-27 EP EP18756868.8A patent/EP3585418A4/en not_active Withdrawn
- 2018-02-27 WO PCT/US2018/020037 patent/WO2018157162A1/en not_active Ceased
- 2018-02-27 CA CA3054127A patent/CA3054127A1/en active Pending
- 2018-02-27 WO PCT/US2018/020040 patent/WO2018157165A1/en not_active Ceased
- 2018-02-27 CN CN201880013956.1A patent/CN110381983B/zh active Active
- 2018-02-27 CA CA3054133A patent/CA3054133A1/en active Pending
- 2018-02-27 BR BR112019017298A patent/BR112019017298A2/pt unknown
-
2019
- 2019-06-28 PH PH12019501533A patent/PH12019501533A1/en unknown
- 2019-08-20 ZA ZA2019/05488A patent/ZA201905488B/en unknown
-
2020
- 2020-04-24 US US16/857,787 patent/US10899817B2/en active Active
- 2020-09-10 US US17/017,108 patent/US10927159B2/en active Active
-
2022
- 2022-04-06 US US17/714,912 patent/US20220227831A1/en not_active Abandoned
- 2022-04-11 US US17/717,740 patent/US12071465B2/en active Active
- 2022-08-18 JP JP2022130749A patent/JP2022159510A/ja active Pending
- 2022-08-18 AU AU2022218575A patent/AU2022218575A1/en not_active Abandoned
-
2023
- 2023-04-06 JP JP2023062366A patent/JP7620045B2/ja active Active
-
2024
- 2024-03-04 US US18/594,400 patent/US20240190939A1/en not_active Abandoned
- 2024-07-17 US US18/775,288 patent/US20240368242A1/en active Pending
-
2025
- 2025-01-09 JP JP2025003769A patent/JP2025061180A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508068A5 (enExample) | ||
| JP7829773B2 (ja) | Ｉｌ２７受容体結合に関連する組成物および方法 | |
| IL258029B (en) | Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins | |
| JP2018529363A5 (enExample) | ||
| US20160347814A1 (en) | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases | |
| KR20210013160A (ko) | 다중-특이적 결합 단백질 및 그에 대한 개선 | |
| JP6242484B2 (ja) | 特定の改善されたヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子 | |
| JP2018521008A (ja) | 腫瘍形成を処置するための治療用組成物および治療方法 | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| HK1259190A1 (zh) | 嵌合抗原受体相关的方法和组合物 | |
| TW201008580A (en) | Dual variable domain immunoglobulin and uses thereof | |
| TW201006485A (en) | Dual variable domain immunoglobulins and uses thereof | |
| TW201109438A (en) | Dual variable domain immunoglobulins and uses thereof | |
| CN103282380A (zh) | 红细胞结合性治疗剂 | |
| JP6154895B2 (ja) | ヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子 | |
| TW200922616A (en) | FOXM1 peptide and medicinal agent comprising the same | |
| CA3044424C (en) | Fractal combination therapy | |
| JP2020508063A5 (enExample) | ||
| CN103965363A (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| CN102725311A (zh) | 治疗发炎的方法 | |
| IL282193B2 (en) | Nk engager molecules and methods of use thereof | |
| JP2022512541A (ja) | Ｐｄ－１系キメラタンパク質を含む併用療法 | |
| JP6933724B2 (ja) | Ｎｋ細胞活性化融合タンパク質、ｎｋ細胞およびそれらを含む医薬組成物 | |
| CN112125975A (zh) | Pd-l1和cd47双特异性融合蛋白及其医药用途 | |
| CN115023435B (zh) | 免疫治疗化合物和方法 |